Board of Directors

Kazumi is the CEO of Redona Therapeutics, which she co-founded alongside prominent Harvard investigators. She is passionate about creating companies focused on novel and emerging areas of biology. Previously, Kazumi was co-founder and CEO of Mitobridge, a start-up pioneering mitochondrial drugs for muscle and kidney diseases. Mitobridge was acquired by Astellas in 2018.

She was also a co-founder and start-up CEO of Epizyme, a leader in novel epigenetic therapeutics, and Primera Diagnostics, a molecular diagnostics company focused on infectious disease and oncology. She has also been a Managing Director at MPM Capital. Kazumi started her career at Abbott and rose through the ranks at Millennium to become SVP of Drug Discovery. She is presently a board member of the Sanford Burnham Institute.

Kazumi received her Ph.D. in Synthetic Chemistry from UC Berkeley.